291 related articles for article (PubMed ID: 31020720)
1. Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KK/Ta mice.
Tanimura Y; Aoi W; Mizushima K; Higashimura Y; Naito Y
Exp Physiol; 2019 Jul; 104(7):1051-1060. PubMed ID: 31020720
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
Diabetes Obes Metab; 2024 Jun; 26(6):2339-2348. PubMed ID: 38504118
[TBL] [Abstract][Full Text] [Related]
3. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
[TBL] [Abstract][Full Text] [Related]
4. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2
Fujita H; Otomo H; Takahashi Y; Yamada Y
Biochem Biophys Res Commun; 2022 Dec; 635():84-91. PubMed ID: 36265286
[TBL] [Abstract][Full Text] [Related]
6. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
McKillop AM; Stevenson CL; Moran BM; Abdel-Wahab YHA; Flatt PR
Peptides; 2018 Feb; 100():165-172. PubMed ID: 29412816
[TBL] [Abstract][Full Text] [Related]
7. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
Sakai Y; Chen G; Ni Y; Zhuge F; Xu L; Nagata N; Kaneko S; Ota T; Nagashimada M
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32790863
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice.
Silva-Veiga FM; Miranda CS; Vasques-Monteiro IML; Souza-Tavares H; Martins FF; Daleprane JB; Souza-Mello V
World J Gastroenterol; 2022 May; 28(17):1814-1829. PubMed ID: 35633911
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patel BD; Bhadada SV; Ghate MD
Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
[TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.
Kim MK; Chae YN; Ahn GJ; Shin CY; Choi SH; Yang EK; Sohn YS; Son MH
Arch Pharm Res; 2017 Feb; 40(2):268-281. PubMed ID: 27885461
[TBL] [Abstract][Full Text] [Related]
11. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
12. A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans.
Nath S; Ghosh SK; Choudhury Y
J Pharmacol Toxicol Methods; 2017; 84():20-30. PubMed ID: 27773844
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
Yisireyili M; Takeshita K; Hayashi M; Wu H; Uchida Y; Yamamoto K; Kikuchi R; Hao CN; Nakayama T; Cheng XW; Matsushita T; Nakamura S; Murohara T
Psychoneuroendocrinology; 2016 Nov; 73():186-195. PubMed ID: 27509090
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice.
Varin EM; Hanson AA; Beaudry JL; Nguyen MA; Cao X; Baggio LL; Mulvihill EE; Drucker DJ
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32663193
[TBL] [Abstract][Full Text] [Related]
17. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
Fukuda-Tsuru S; Kakimoto T; Utsumi H; Kiuchi S; Ishii S
Eur J Pharmacol; 2014 Jan; 723():207-15. PubMed ID: 24309217
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
Lee M; Shin E; Bae J; Cho Y; Lee JY; Lee YH; Lee BW; Kang ES; Cha BS
Sci Rep; 2020 Nov; 10(1):19429. PubMed ID: 33173107
[TBL] [Abstract][Full Text] [Related]
19. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
Said S; Nwosu AC; Mukherjee D; Hernandez GT
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibition protects the liver of insulin-resistant female rats against triglyceride accumulation by suppressing uric acid.
Omolekulo TE; Michael OS; Olatunji LA
Biomed Pharmacother; 2019 Feb; 110():869-877. PubMed ID: 30557836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
